Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corbus Pharma (CRBP)

Corbus Pharma (CRBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,330
  • Shares Outstanding, K 125,256
  • Annual Sales, $ 880 K
  • Annual Income, $ -45,640 K
  • 60-Month Beta 2.03
  • Price/Sales 48.43
  • Price/Cash Flow N/A
  • Price/Book 0.71
Trade CRBP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings -0.08 on 05/10/22
  • Next Earnings Date 05/12/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 118.00% ( -158.68%)
  • Historical Volatility 123.62%
  • IV Percentile 46%
  • IV Rank 6.44%
  • IV High 1,056.58% on 02/23/22
  • IV Low 53.44% on 04/06/22
  • Put/Call Vol Ratio 0.40
  • Today's Volume 7
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 20,392
  • Open Int (30-Day) 20,580

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2080 +50.96%
on 05/12/22
0.4078 -23.00%
on 05/16/22
-0.0464 (-12.87%)
since 04/22/22
3-Month
0.2080 +50.96%
on 05/12/22
0.6240 -49.68%
on 03/25/22
-0.0121 (-3.71%)
since 02/23/22
52-Week
0.2080 +50.96%
on 05/12/22
2.2900 -86.29%
on 06/09/21
-1.4560 (-82.26%)
since 05/21/21

Most Recent Stories

More News
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CRBP : 0.3140 (-7.92%)
CASI : 0.3794 (-1.30%)
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

MRK : 93.83 (+0.30%)
CORT : 20.05 (-1.81%)
CRBP : 0.3140 (-7.92%)
SLNO : 0.1998 (+8.59%)
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

PCRX : 63.11 (-0.75%)
XNCR : 22.75 (-3.40%)
CRBP : 0.3140 (-7.92%)
SLNO : 0.1998 (+8.59%)
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

ZTS : 163.00 (+0.27%)
XNCR : 22.75 (-3.40%)
CRBP : 0.3140 (-7.92%)
SLNO : 0.1998 (+8.59%)
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

NERV : 0.3600 (-3.25%)
CRBP : 0.3140 (-7.92%)
ALVR : 4.00 (+2.83%)
GMTX : 1.3600 (+0.74%)
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

NERV : 0.3600 (-3.25%)
CRBP : 0.3140 (-7.92%)
CTXR : 0.9011 (-1.51%)
GMTX : 1.3600 (+0.74%)
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study

Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.

MRK : 93.83 (+0.30%)
CORT : 20.05 (-1.81%)
ONTX : 1.1200 (+2.75%)
CRBP : 0.3140 (-7.92%)
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

NERV : 0.3600 (-3.25%)
CRBP : 0.3140 (-7.92%)
ALVR : 4.00 (+2.83%)
GMTX : 1.3600 (+0.74%)
Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals

Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.

BKE : 29.71 (-1.23%)
CRI : 75.37 (-0.11%)
CRBP : 0.3140 (-7.92%)
IQ : 4.00 (-2.68%)
TH : 5.94 (-2.46%)
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.

BKE : 29.71 (-1.23%)
CRBP : 0.3140 (-7.92%)
IQ : 4.00 (-2.68%)
TH : 5.94 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 0.3602
2nd Resistance Point 0.3458
1st Resistance Point 0.3299
Last Price 0.3140
1st Support Level 0.2996
2nd Support Level 0.2852
3rd Support Level 0.2693

See More

52-Week High 2.2900
Fibonacci 61.8% 1.4947
Fibonacci 50% 1.2490
Fibonacci 38.2% 1.0033
Last Price 0.3140
52-Week Low 0.2080

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar